PO-REN HSUEHLiu C.-Y.Shi Z.-Y.Lee M.-H.Chang F.-Y.Yang M.-C.2020-12-182020-12-1820100924-8579https://scholars.lib.ntu.edu.tw/handle/123456789/528647[SDGs]SDG3cefepime; ceftriaxone; flomoxef; piperacillin plus tazobactam; abdominal infection; adult; biliary tract infection; controlled study; cost effectiveness analysis; cost minimization analysis; drug cost; drug safety; evidence based medicine; female; gastrointestinal infection; health care cost; health care utilization; human; length of stay; letter; liver abscess; major clinical study; male; medical record review; peritonitis; practice guideline; priority journal; retroperitoneal abscess; spleen abscess; Taiwan; treatment outcome; unspecified side effect; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Costs and Cost Analysis; Female; Humans; Male; Middle Aged; Peritonitis; Retrospective Studies; Taiwan; Young Adultletter10.1016/j.ijantimicag.2009.09.004198895182-s2.0-70849098467